keyword
MENU ▼
Read by QxMD icon Read
search

teriparatide

keyword
https://www.readbyqxmd.com/read/28323910/progressive-development-of-pth-resistance-in-patients-with-inactivating-mutations-on-the-maternal-allele-of-gnas
#1
Alessia Usardi, Asmaa Mamoune, Elodie Nattes, Jean-Claude Carel, Anya Rothenbuhler, Agnès Linglart
Background: PTH resistance is characterized by hypocalcaemia, hyperphosphatemia and elevated PTH in absence of vitamin D deficiency. Pseudohypoparathyroidism (PHP) type 1A (or iPPSD2, inactivating Signaling PTH/PTHrp Disorder 2 according to the new classification) is caused by mutations in the maternal GNAS allele. Objective: To assess PTH resistance over time in 20 patients affected by iPPSD2 (PHP1A), diagnosed because of family history, ectopic ossification or short stature and carrying a GNAS mutation...
February 21, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28314897/transient-osteoporosis-of-the-hip-review-of-the-literature
#2
REVIEW
K Asadipooya, L Graves, L W Greene
Transient osteoporosis of the hip (TOH) is a temporary clinical condition of unknown etiology which usually resolves with conservative therapy though may be complicated by fracture or progression to avascular necrosis (AVN). TOH may be slightly more prevalent in men but when it occurs in women, it is most often seen in the latter part of pregnancy. Though fracture is a rare complication of TOH when it occurs, it is most often associated with TOH occurring in pregnancy. Magnetic resonance imaging (MRI) is the best method to diagnosis TOH...
March 17, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28303448/parathyroid-hormone-and-parathyroid-hormone-related-protein-analogs-in-osteoporosis-therapy
#3
REVIEW
Benjamin Z Leder
PURPOSE OF REVIEW: The purpose is to review the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment. RECENT FINDINGS: The parathyroid hormone analog teriparatide, a potent stimulator of bone remodeling, increases hip and spine bone mineral density and reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporotic women. The parathyroid hormone-related protein analog, abaloparatide, also reduces fracture incidence but has pharmacological effects that differ from teriparatide, particularly in cortical bone...
March 16, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28293779/effect-of-osteoporosis-medication-on-changes-in-bone-mineral-density-and-bone-turnover-markers-after-24-month-administration-of-daily-teriparatide-comparison-among-minodronate-raloxifene-and-eldecalcitol
#4
Shinichi Nakatoh
This study reveals the changes in bone mineral density (BMD), the turnover rate, and the balance [multiple of median formation/multiple of median resorption (MoMf/MoMr)] affected by the selection of different bone resorption inhibitors after 24-month daily teriparatide (20 µg/day) administration. The turnover rate was calculated as √(MoMf(2) + MoMr(2)), where MoMf = bone-specific alkaline phosphatase (BAP) value/18.6 and MoMr = tartrate-resistant acid phosphatase 5b (TRACP-5b) value/463. One hundred and twenty-one osteoporotic women (mean age 82...
March 14, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/28287044/no-effect-of-teriparatide-on-migration-in-total-knee-replacement
#5
Håkan Ledin, Lars Good, Torsten Johansson, Per Aspenberg
Background and purpose - Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fixation. We used radiostereometric analysis (RSA) to investigate whether teriparatide influences prosthesis fixation. Early migration as measured by RSA can predict future loosening. Patients and methods - In a randomized controlled trial with blind evaluation, 50 patients with osteoarthritis of the knee were allocated to a teriparatide treatment group (Forsteo, 20 μg daily for 2 months postoperatively) or to an untreated control group...
March 13, 2017: Acta Orthopaedica
https://www.readbyqxmd.com/read/28286299/importance-of-prompt-antiresorptive-therapy-in-postmenopausal-women-discontinuing-teriparatide-or-denosumab-the-denosumab-and-teriparatide-follow-up-study-data-follow-up
#6
Benjamin Z Leder, Joy N Tsai, Linda A Jiang, Hang Lee
When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly decreases. To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional prescription osteoporosis medications to women who discontinue these drugs followed by prompt antiresorptive therapy, we asked women concluding the Denosumab and Teriparatide Administration (DATA) study and its extension, DATA-Switch, to return for BMD measurements 1-2years after study completion...
March 9, 2017: Bone
https://www.readbyqxmd.com/read/28279202/systemic-administration-of-mesenchymal-stem-cells-combined-with-parathyroid-hormone-therapy-synergistically-regenerates-multiple-rib-fractures
#7
Doron Cohn Yakubovich, Dmitriy Sheyn, Maxim Bez, Yeshai Schary, Eran Yalon, Afeef Sirhan, May Amira, Alin Yaya, Sandra De Mel, Xiaoyu Da, Shiran Ben-David, Wafa Tawackoli, Eric J Ley, Dan Gazit, Zulma Gazit, Gadi Pelled
BACKGROUND: A devastating condition that leads to trauma-related morbidity, multiple rib fractures, remain a serious unmet clinical need. Systemic administration of mesenchymal stem cells (MSCs) has been shown to regenerate various tissues. We hypothesized that parathyroid hormone (PTH) therapy would enhance MSC homing and differentiation, ultimately leading to bone formation that would bridge rib fractures. METHODS: The combination of human MSCs (hMSCs) and a clinically relevant PTH dose was studied using immunosuppressed rats...
March 9, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28255336/bone-modeling-and-remodeling-potential-as-therapeutic-targets-for-the-treatment-of-osteoporosis
#8
REVIEW
Bente Langdahl, Serge Ferrari, David W Dempster
The adult skeleton is renewed by remodeling throughout life. Bone remodeling is a process where osteoclasts and osteoblasts work sequentially in the same bone remodeling unit. After the attainment of peak bone mass, bone remodeling is balanced and bone mass is stable for one or two decades until age-related bone loss begins. Age-related bone loss is caused by increases in resorptive activity and reduced bone formation. The relative importance of cortical remodeling increases with age as cancellous bone is lost and remodeling activity in both compartments increases...
December 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28249967/atypical-femoral-fractures-related-to-bisphosphonate-treatment-issues-and-controversies-related-to-their-surgical-management
#9
A Koh, E Guerado, P V Giannoudis
AIMS: Treatment guidelines for atypical femoral fractures associated with bisphosphonates have not been established. We conducted a systematic review of the treatment of atypical femoral fractures first, to evaluate the outcomes of surgical fixation of complete atypical fractures and secondly, to assess whether prophylactic surgery is necessary for incomplete atypical fractures. MATERIALS AND METHODS: Case reports and series were identified from the PubMed database and were included if they described the treatment of atypical femoral fractures...
March 2017: Bone & Joint Journal
https://www.readbyqxmd.com/read/28247298/efficacy-of-daily-teriparatide-treatment-in-low-levels-of-walking-state-patients
#10
Rui Niimi, Toshibumi Kono, Atsushi Nishihara, Masahiro Hasegawa, Toshihiko Kono, Akihiro Sudo
INTRODUCTION: Little is known about the efficacy of osteoporosis medication in patients with low levels of walking state, namely, influence by immobilization levels. We retrospectively compared the efficacy of the daily teriparatide therapy in patients with low and high levels of walking state to detect possible immobilization-related differences. METHODS: We analyzed 661 patients treated with 20 μg/day of teriparatide for 24 months. We measured the changes in the bone mineral density (BMD) of the lumbar spine (LS) and of the femoral neck (FN), the changes in serum procollagen type I N-terminal propeptide (PINP) levels and urinary N-telopeptide (uNTX) excretion...
February 28, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28244922/teriparatide-enhancement-of-lumbar-fusion-bone-enhancement-versus-cost-convenience-and-risk-of-cancer-commentary-on-an-article-by-shigeto-ebata-md-phd-et-al-role-of-weekly-teriparatide-administration-in-osseous-union-enhancement-within-six-months-after-posterior
#11
https://www.readbyqxmd.com/read/28244906/role-of-weekly-teriparatide-administration-in-osseous-union-enhancement-within-six-months-after-posterior-or-transforaminal-lumbar-interbody-fusion-for-osteoporosis-associated-lumbar-degenerative-disorders-a-multicenter-prospective-randomized-study
#12
RANDOMIZED CONTROLLED TRIAL
Shigeto Ebata, Jun Takahashi, Tomohiko Hasegawa, Keijiro Mukaiyama, Yukihiro Isogai, Tetsuro Ohba, Yosuke Shibata, Toshiyuki Ojima, Zentaro Yamagata, Yukihiro Matsuyama, Hirotaka Haro
BACKGROUND: For elderly patients, posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) is usually performed to treat lumbar degenerative diseases. However, some patients exhibit pseudarthrosis following such procedures. The anabolic agent teriparatide is an approved treatment for promoting bone formation in osteoporotic patients. Our multicenter, prospective randomized study assessed the role of once-weekly teriparatide administration on patient outcomes following interbody fusion...
March 1, 2017: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/28228782/safety-and-effectiveness-of-teriparatide-vs-alendronate-in-postmenopausal-osteoporosis-a-prospective-non-randomized-clinical-study
#13
Gianfilippo Caggiari, Paolo Tranquilli Leali, Giulia Raffaella Mosele, Leonardo Puddu, Francesca Badessi, Carlo Doria
In this work we study the safety and effectiveness of teriparatide and alendronate in patients with postmenopausal osteoporosis at high risk of fracture; it was a double-blinded and it was done by examining the comparisons between teriparatide 20 μg/day and alendronate 10 mg/day. Safety and effectiveness analyses were based on data from 355 woman with a mean age of 68 years. Two groups (A and B) with T-score ≤-2.5 at bone mineral density were analyzed and 3 or more vertebral fractures on radiograph. Group A: was treated with teriparatide 20 μg/day and composed from 182 women, in post-menopausal age, without a history of cancer...
September 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28225309/anabolic-bone-window-with-weekly-teriparatide-therapy-in-post-menopausal-osteoporosis-a-pilot-study
#14
Vinaya Gopalaswamy, Deba Prasad Dhibar, Vipin Gupta, Ashutosh Kumar Arya, Niranjan Khandelwal, Anil Bhansali, Sudhir Kumar Garg, Neelam Agarwal, Sudhaker D Rao, Sanjay Kumar Bhadada
BACKGROUND: Osteoporosis is a major public health problem, which reduces bone strength and increases risk of fracture. Teriparatide is an established and the only currently available anabolic therapy for the treatment of postmenopausal osteoporosis (PMO) with recommended daily dose of 20 μg subcutaneously. However data regarding the long term effect of once-weekly teriparatide therapy on bone mineral density (BMD), bone turnover markers (BTMs) and anabolic bone window is limited. METHODS: In this prospective observational study, 26 patients with PMO were treated with weekly teriparatide therapy (60 μg) for 2 years...
February 22, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28218468/igf-1-receptor-expression-on-circulating-osteoblast-progenitor-cells-predicts-tissue-based-bone-formation-rate-and-response-to-teriparatide-in-premenopausal-women-with-idiopathic-osteoporosis
#15
Adi Cohen, Stavroula Kousteni, Brygida Bisikirska, Jayesh G Shah, J Sanil Manavalan, Robert R Recker, Joan Lappe, David W Dempster, Hua Zhou, Donald J McMahon, Mariana Bucovsky, Mafo Kamanda-Kosseh, Julie Stubby, Elizabeth Shane
We have previously reported that premenopausal women with idiopathic osteoporosis (IOP) have profound microarchitectural deficiencies and heterogeneous bone remodeling. Those with the lowest bone formation rate have higher baseline serum IGF-1 levels and less robust response to teriparatide. Because IGF-1 stimulates bone formation and is critical for teriparatide action on osteoblasts, these findings suggest a state of IGF-1 resistance in some IOP women. To further investigate the hypothesis that osteoblast and IGF-1 related mechanisms mediate differential responsiveness to teriparatide in IOP, we studied circulating osteoblast progenitor (COP) cells and their IGF-1 receptor (IGF-1R) expression...
February 20, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28217686/pregnancy-related-osteoporosis-and-spinal-fractures
#16
Ka Yeong Yun, Si Eun Han, Seung Chul Kim, Jong Kil Joo, Kyu Sup Lee
Pregnancy-related osteoporosis is a very rare condition characterized by the occurrence of fracture during pregnancy or the puerperium. Despite its relative rarity, it can be a dangerous condition that causes severe back pain, height loss and disability. Normal physiologic changes during pregnancy, genetic or racial difference, obstetrical history and obstetrical disease, such as preterm labor or pregnancy-induced hypertension, are presumed risk factors of pregnancy-related osteooporosis. However, exact etiology and pathogenesis are uncertain...
January 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28193537/preparation-characterization-and-in-vivo-evaluation-of-a-combination-delivery-system-based-on-hyaluronic-acid-jeffamine-hydrogel-loaded-with-phbv-plga-blend-nanoparticles-for-prolonged-delivery-of-teriparatide
#17
Nika Bahari Javan, Hamed Montazeri, Leila Rezaie Shirmard, Nersi Jafary Omid, Ghullam Reza Barbari, Mohsen Amini, Mohammad Hossein Ghahremani, Morteza Rafiee-Tehrani, Farid Abedin Dorkoosh
In the current study, biodegradable PHBV/PLGA blend nanoparticles (NPs) containing Teriparatide were loaded in hyaluronic acid/jeffamine (HA-JEF ED-600) hydrogel to prepare a combination delivery system (CDS) for prolonged delivery of Teriparatide. The principal purpose of the present study was to formulate an effective and prolonged Teriparatide delivery system in order to reduce the frequency of injection and thus enhance patient's compliance. Morphological properties, swelling behaviour, crosslinking efficiency and rheological characterization of HA-JEF ED-600 hydrogel were evaluated...
April 1, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28164049/a-case-report-of-bisphosphonate-induced-bilateral-osteoporotic-subtrochanteric-fracture-femurii-review-of-literature
#18
Rajendra Uppin, Srinath Gupta, Shivank Prakash
INTRODUCTION: Osteoporosis is a significant health-care problem characterized by excessive skeletal fragility, susceptibility to low-trauma fractures in men as well as women. Any abnormality of the bone that reduces the strength of the bone predisposes it to mechanical failure during normal activity or with minimum trauma. The mechanical failure manifests itself as a fracture, and this fracture must be recognized as a pathological fracture if the patient is to be treated properly. Osteoporosis is one of the leading causes of such pathological fractures and accounts for 1...
September 2016: Journal of Orthopaedic Case Reports
https://www.readbyqxmd.com/read/28159062/abaloparatide-recombinant-human-pthrp-1-34-anabolic-therapy-for-osteoporosis
#19
REVIEW
Chee Kian Chew, Bart L Clarke
The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1-34 [rhPTH (1-34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1-34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide...
March 2017: Maturitas
https://www.readbyqxmd.com/read/28155140/teriparatide-treatment-of-femoral-fracture-nonunion-that-autogenous-bone-grafting-failed-to-heal-a-case-report
#20
Wei Yu, Xiaodong Guo
PURPOSE: Management of fracture nonunion is challenging as another surgical intervention for the patient is often a necessity, which has a huge impact on both quality of life and economic burden of the patient. Thus, a less aggressive and better accepted treatment for nonunion is required. METHODS: We gave teriparatide to a 45-year-old man with femoral fracture nonunion 1 year after he underwent surgery with autogenous bone grafting that failed to heal his initial nonunion...
December 2017: Archives of Osteoporosis
keyword
keyword
112
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"